Biogen Inc. (NASDAQ: BIIB) was raised to Buy from Hold at Canaccord Genuity. The 52-week trading range for the biotech giant is $248.61 to $370.57. The Wall Street consensus price target is set at $350.04. The shares closed Wednesday at $294.40, up almost 3% on the day, and were also higher in premarket action Thursday morning.